Myriad Genetics (MYGN) SEC Filings: History & Chart

Myriad Genetics, Inc.(MYGN)

Medical - Diagnostics & Research · Salt Lake City, UT

$4.28-0.30 (-6.55%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Myriad Genetics, Inc.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Salt Lake City, UT

2,700 employees

www.myriad.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Samraat S. Raha

View full financials

Form	Filing Date	Accepted	Document
4	Sep 22, 2026	Sep 22, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
4	Sep 17, 2026	Sep 17, 2026	View filing
3	Sep 17, 2026	Sep 17, 2026	View filing
8-K	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 8, 2026	Sep 8, 2026	View filing
SC 13G	Sep 4, 2026	Sep 4, 2026	View filing
4	Aug 17, 2026	Aug 17, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
10-Q	Jul 31, 2026	Jul 31, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
8-K	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
8-K	Jun 4, 2026	Jun 4, 2026	View filing
S-8	Jun 4, 2026	Jun 4, 2026	View filing
S-8	Jun 4, 2026	Jun 4, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing

SEC Filings

Recent Filings